Strategies to examine new compounds for intraperitoneal use in ovarian cancer.
The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena.
Markman
M
M
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mmarkman@mdanderson.org
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents